Distributor inventory | Tablet
Tofacitinib 11 mg (extended-release)
Treatment of moderate to severe rheumatoid arthritis, psoriatic arthritis, and moderate to severe ulcerative colitis (as prescribed by a specialist), usually when there is inadequate response/intolerance to other DMARDs/biologics
Tofacitinib is a Janus kinase (JAK) inhibitor that reduces signaling of multiple inflammatory cytokines. This lowers immune-mediated inflammation and helps relieve symptoms and prevent disease progression in autoimmune conditions.
Tablet (extended-release): take exactly as prescribed, usually once daily. Swallow whole with water; do not crush, break or chew. Can be taken with or without food; take at the same time each day. Regular lab monitoring (CBC, LFTs, lipids) is typically required.
Common side effects of TOFABRINT 11MG TAB may include:
Prescription-only immunosuppressant. Increased risk of serious infections (TB, bacterial, fungal, viral) and reactivation (TB/hepatitis); screen for TB and hepatitis before therapy and monitor. Risk of malignancy (including lymphoma and skin cancer), major adverse cardiovascular events, blood clots (DVT/PE) and death—use with caution especially in older patients, smokers, and those with CV risk factors; seek urgent care for chest pain, breathlessness, leg swelling. Monitor CBC (risk of anemia/neutropenia/lymphopenia), liver function and lipids. Avoid live vaccines during treatment; complete immunizations before starting if possible. Use caution/adjustment in hepatic or renal impairment as advised by doctor.
